Addex Therapeutics (FRA:APE) Buyback Yield %: -17.93 (As of Jul. 05, 2026)


What is Addex Therapeutics Buyback Yield %?

Addex Therapeutics FRA:APE -2.38% Buyback Yield % is -17.93 as of Jul. 05, 2026. The stock has 6 warning signs investors should review. Among 741 Biotechnology companies, Addex Therapeutics ranks worse than 65.18% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Addex Therapeutics's current buyback yield was -17.93%.

Addex Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Addex Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Addex Therapeutics Buyback Yield % Chart

Addex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.12 -1.62 -1.89 -0.17 -20.38

Addex Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.01 -11.36 -14.79 -18.37 -25.42

FRA:APE vs VRTX, REGN, ALNY: Buyback Yield % Comparison

For the Biotechnology subindustry, Addex Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Addex Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Addex Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Addex Therapeutics's Buyback Yield % falls into.


Addex Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Addex Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-0.031 + 1.317) / 6.3090945
=-20.38%

Addex Therapeutics's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (-0.034 + 1.287) / 4.3551435
=-28.77%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -17.93 mean?
Addex Therapeutics (FRA:APE) has a Buyback Yield % of -17.93 as of Jul. 05, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Addex Therapeutics and its competitors. According to the industry distribution chart, Addex Therapeutics ranks #483 out of 741 companies in the Biotechnology industry, placing it in the top 65.2%.
Is Addex Therapeutics' Buyback Yield % too high?
Addex Therapeutics' current Buyback Yield % is -17.93. Based on the distribution chart, Addex Therapeutics ranks #483 out of 741 companies in the Biotechnology industry, which is below the industry midpoint.
How does Addex Therapeutics' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Addex Therapeutics ranks #483 out of 741 companies for Buyback Yield %. This places Addex Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Addex Therapeutics and its competitors. Addex Therapeutics's current Buyback Yield % is -17.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Addex Therapeutics (FRA:APE) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.01, compared to a current price of €0.04 — trading 310% above its estimated fair value. The current Buyback Yield % is -17.93. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Addex Therapeutics (FRA:APE), the current Buyback Yield % is -17.93 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Addex Therapeutics Business Description

Address Chemin des Mines 9, Geneva, CHE, 1202
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.